NovelStem International Corp.

Equities

NSTM

US67001V1098

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:07:06 24/04/2024 BST			5-day change	1st Jan Change
0.06 ^USD	-.--%		-.--%	-4.61%

04-01	NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Novelstem International Corp. Appoints Jan Loeb as President

January 17, 2023 at 08:55 pm

On January 13, 2023, the Board of Directors of Novelstem International Corp. appointed Mr. Jan Loeb as President. Mr. Loeb has served as Chairman of the Company's Board of Directors since July 2018 and as Executive Chairman since September 2022.

Latest news about NovelStem International Corp.

NovelStem International Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-17	CI
NovelStem International Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
NovelStem International Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Novelstem International Corp. Appoints Jan Loeb as President	17/01/23	CI
NovelStem International Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
NovelStem International Corp. Elects Christine Jenkins as Chief Financial Officer	04/10/22	CI
NovelStem International Corp. Elects Jan Loeb as Principal Executive Officer	04/10/22	CI
NovelStem International Corp. Announces Management Changes	04/10/22	CI
NovelStem International Corp and Newstem Ltd. Announce New Research Collaborations for Stem-Cell Technology Platform in Cancer Immunotherapy and Covid-19 Resistance	21/04/20	CI
NovelStem International Corp.'s Equity Buyback announced on January 16, 2018, has expired.	14/01/19	CI
Hollywood Media Corp. will Change its Ticker to NSTM from HOLL	26/09/18	CI
Hollywood Media Corp. has Changed its Name to NovelStem International Corp	25/09/18	CI
Hollywood Media Corp. Announces Board Changes	16/07/18	CI
NewStem Ltd. announced that it expects to receive $4 million in funding from Hollywood Media Corp.	15/07/18	CI
Hollywood Media Corp. Provides Update on Mechanics of Special One-Time Distribution, Payable on March 29, 2018	01/03/18	CI
Hollywood Media Corp. Announces Cash Distribution, Payable March 30, 2018	16/01/18	CI
Hollywood Media Corp. authorizes a Buyback Plan.	15/01/18	CI
Hollywood Media Corp. announces an Equity Buyback for 1,000,000 shares.	15/01/18	CI
Fandango Media, LLC completed the acquisition of MovieTickets.com, Inc. from National Amusements, Inc., Cineplex Entertainment Corporation, Regal Entertainment Group, The Marcus Corporation, Viacom, Inc., Time Warner Inc. and others.	30/12/17	CI
Fandango Media, LLC signed a definitive agreement to acquire MovieTickets.com, Inc. from National Amusements, Inc., Cineplex Entertainment Corporation, Regal Entertainment Group, The Marcus Corporation, Viacom, Inc., Time Warner Inc. and others.	12/10/17	CI
Hollywood Media Corp.’s Equity Buyback announced on September 28, 2007 has expired.	20/11/14	CI
Hollywood Media Corp. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013	07/04/14	CI
Hollywood Media Corp.(OTCPK:HOLL) dropped from NASDAQ Composite Index	17/02/14	CI
Hollywood Media Corp Considering Multiple Strategic Alternatives	28/01/14	CI

Chart NovelStem International Corp.

Duration

Period

More charts

Company Profile

NovelStem International Corp. is a development-stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patientsâ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NOVELSTEM INTERNATIONAL CORP.	-4.61%	2.81M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs